276 filings
DEF 14A
ESPR
Esperion Therapeutics Inc.
Definitive proxy
11 Apr 24
4:21pm
ARS
2023 FY
ESPR
Esperion Therapeutics Inc.
11 Apr 24
Annual report to shareholders
4:19pm
10-K
2023 FY
ESPR
Esperion Therapeutics Inc.
Annual report
27 Feb 24
9:19am
8-K
ESPR
Esperion Therapeutics Inc.
27 Feb 24
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
7:23am
8-K
ESPR
Esperion Therapeutics Inc.
22 Jan 24
Esperion Announces Proposed Public Offering of Common Stock
6:10am
424B5
pvlkp64byahh6uh7 k54
22 Jan 24
Prospectus supplement for primary offering
6:04am
8-K
1u5erfs7
18 Jan 24
Regulation FD Disclosure
4:03pm
424B5
3qkza3lfv zln5x
18 Jan 24
Prospectus supplement for primary offering
4:01pm
8-K
mcq90
11 Jan 24
Results of Operations and Financial Condition
4:09pm
8-K
183v37ze7eu k066lvvf
3 Jan 24
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
8:00am
8-K
mnk7 rob86r0c
7 Nov 23
Esperion Reports Third Quarter 2023 Financial Results
7:30am
S-8
rznnxx 583
24 Aug 23
Registration of securities for employees
9:29am
S-8
zar7r7apy0q43v4 h7
1 Aug 23
Registration of securities for employees
9:02am
8-K
lhu73aj xgim
1 Aug 23
Esperion Reports Second Quarter 2023 Financial Results
7:07am
8-K
p0lrnxr
26 Jun 23
Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions
6:03am
8-K
ht1nhk21246f57j6wci
15 Jun 23
Departure of Directors or Certain Officers
4:56pm
DEFA14A
wxtswyf i0
25 May 23
Additional proxy soliciting materials
4:39pm